Provided by Tiger Trade Technology Pte. Ltd.

Werewolf Therapeutics, Inc.

0.8900
+0.00670.76%
Post-market: 0.8765-0.0135-1.52%19:58 EDT
Volume:6.43M
Turnover:5.68M
Market Cap:43.20M
PE:-1.19
High:0.9344
Open:0.8656
Low:0.8400
Close:0.8833
52wk High:2.38
52wk Low:0.2700
Shares:48.54M
Float Shares:47.91M
Volume Ratio:0.09
T/O Rate:13.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7503
EPS(LYR):-1.3300
ROE:-119.86%
ROA:-27.39%
PB:2.65
PE(LYR):-0.67

Loading ...

Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation

Simply Wall St.
·
May 14

Werewolf Therapeutics director Luke Evnin sells 44,679 shares worth $24,127.66

Reuters
·
May 14

Werewolf Therapeutics director Luke Evnin disposes 407,574 shares for $294,971.41

Reuters
·
May 13

RA Capital Management disposes 565,167 Werewolf Therapeutics shares worth $389,277

Reuters
·
May 13

Werewolf Therapeutics director Luke Evnin disposes of USD 63,622 common shares

Reuters
·
May 08

Werewolf Therapeutics Q1 EPS $(0.28), Inline

Benzinga Earnings
·
May 08

Werewolf Therapeutics Q1 net loss narrows to $13.5 million; R&D expenses drop to $8.2 million

Reuters
·
May 08

Press Release: Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Dow Jones
·
May 08

Werewolf Therapeutics director Luke Evnin disposes of common shares worth $198,028.71

Reuters
·
May 05

Werewolf Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
Apr 29

Werewolf Therapeutics Faces Nasdaq Delisting Risk After Falling Below $1 Minimum Bid Price

TIPRANKS
·
Mar 28

Werewolf Therapeutics Q4 EPS $(0.20) Beats $(0.35) Estimate

Benzinga Earnings
·
Mar 27

Werewolf Therapeutics FY2025 net loss narrows 13.76% to $61 million; cash and cash equivalents drop 48.6% to $57 million

Reuters
·
Mar 27

Werewolf Therapeutics Q4 Basic EPS USD -0.17

THOMSON REUTERS
·
Mar 27

Werewolf Therapeutics Inc - Initiates Process to Explore Strategic Alternatives

THOMSON REUTERS
·
Mar 27

Press Release: Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Dow Jones
·
Mar 27

Werewolf Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

Reuters
·
Mar 24

U.S. Earnings Preview: Before Market Open March 24

Dow Jones
·
Mar 24

Werewolf Therapeutics Files Initial Beneficial Ownership Statement for Michael J. Urban, VP of Finance & Corporate Controller

Reuters
·
Mar 14

U.S. Earnings Preview: Before Market Open March 10

Dow Jones
·
Mar 10